The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cellular Therapy Core (CTC) consists of the clinical Cell Therapy Laboratory (CTL) in the Weinberg Building and the Process Optimization Laboratory (POL), a designated lab space in the Bunting-Blaustein Cancer Research Building for translational scale-up studies. This Core supports investigator sponsored clinical trials. These include technology transfer from the research laboratory to the clinical setting, scale up and validation studies. The staff within this laboratory has extensive experience in all aspects of cellular therapy including cGMP Phase l/ll manufacturing for autologous products, cGTP manufacturing of blood and bone marrow for transplantation, stem cell biology expertise, immunotherapy expertise and clinical experience in transplantation and cellular therapies. There is extensive QA/QC and regulatory experience for the development of products and compliance with FDA regulations. Staff in this Core also provide assistance in the preparation of regulatory documents including IND applications. Lay: The Cellular Therapy Core provides a critical service to cancer researchers by helping turn their promising laboratory findings into new cancer therapies that can treat patients. The Core staff work in a controlled laboratory with specialized equipment where they process and freeze blood-based stem cells for patients enrolled in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661012
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$225,956
Indirect Cost
$86,760
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Chen, Zhihang; Penet, Marie-France; Krishnamachary, Balaji et al. (2016) PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials 80:57-67
Castanares, Mark A; Copeland, Ben T; Chowdhury, Wasim H et al. (2016) Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. Prostate 76:215-25
Anders, Nicole M; Wanjiku, Teresia M; He, Ping et al. (2016) A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomed Chromatogr 30:494-6
Morgan, Michael T; Haj-Yahya, Mahmood; Ringel, Alison E et al. (2016) Structural basis for histone H2B deubiquitination by the SAGA DUB module. Science 351:725-8
Hurley, Paula J; Sundi, Debasish; Shinder, Brian et al. (2016) Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res 22:448-58
Roberts, Nicholas J; Norris, Alexis L; Petersen, Gloria M et al. (2016) Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov 6:166-75
Morais, Carlos L; Guedes, Liana B; Hicks, Jessica et al. (2016) ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Hum Pathol 55:117-25
Wang, Zhijun; Hansis, Eberhard; Chen, Rongxin et al. (2016) Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility. Minim Invasive Ther Allied Technol 25:162-70
Vrooman, Lynda M; Kirov, Ivan I; Dreyer, ZoAnn E et al. (2016) Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 63:228-33
Sutcliffe, Siobhan; Nevin, Remington L; Pakpahan, Ratna et al. (2016) Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. Int J Cancer 138:2221-30

Showing the most recent 10 out of 1943 publications